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Intravenous fluids (IVFs) represent a basic therapeutic
intervention utilized in septic shock. Unfortunately, the
optimal method for administering IVFs to maximize
patient outcomes is unknown. A meta-analysis of
four randomized trials of goal-directed therapy did
not demonstrate a significant reduction in mortality
(odds ratio 0.609; 95% confidence interval 0.363 to
1.020; P = 0.059), whereas 18 trials with historical
controls showed a significant increase in survival
(odds ratio 0.580; 95% confidence interval 0.501 to
0.672; P < 0.0001). Based on these data, clinicians
should be aware of the potential for harm due to
the excessive administration of IVFs to patients with
septic shock.Introduction
Intravenous fluids (IVFs) are one of the most common
therapies provided to critically ill patients. IVF administra-
tion is largely empiric, although goal-directed approaches
have been used in an attempt to optimize resuscitation in
unstable patients [1,2]. Excessive use of any therapeutic
agent can be associated with potential harm; excessive use
of antibiotics [3,4], sedation [5,6], tidal volume [7,8], trans-
fusions [9], and glucose [10] have all been linked to un-
favorable patient outcomes. It is now recognized that
excessive IVFs may also contribute to new complications
and worsening of underlying disease processes, including
acute respiratory distress syndrome, abdominal compart-
ment syndrome, coagulopathy, and cerebral edema
[11-14]. Unfortunately, a systematic approach for delivery
of IVFs in critically ill patients does not exist. This is partly
related to the various conditions managed in the ICU
setting, as well as the varied approaches to IVF adminis-
tration and availability of different IVF types (that is,* Correspondence: mkollef@dom.wustl.edu
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Goal-directed therapy (GDT) for IVF administration in
the first 6 hours of septic shock is now advocated by
the most recent version of the Surviving Sepsis Cam-
paign guidelines with a 1C evidence recommendation
[1]. However, not all clinicians and investigators are
convinced that this approach is optimal [15,16]. There-
fore, the goal of this review and meta-analysis is to as-
sess the evidence in support of IVFs in septic shock,
focusing on the quantity of IVFs administered, and to
determine if conservative fluid therapy is justifiable in
septic patients. Like many other therapeutic areas in
critical care, an approach to fluid administration that
employs therapeutic minimization may be preferred for
the avoidance of complications and optimization of
patient outcomes.Methods
We conducted an English language search of PubMed
and Cochrane databases from January 1980 to December
2014 to find human trials of sepsis care bundles in
adults (aged ≥18 years) using these search terms: sepsis,
septic shock, treatment, guidelines, protocols, GDT, and
bundles (Figure 1). The studies that were included had to
enroll septic patients, have a control (historical or concur-
rent), and record mortality rates. The included studies also
had to provide targets for their usage of fluids as part of
their sepsis intervention or sepsis bundle. Criteria for sepsis
or septic shock in patients receiving bundled care had to be
consistent with the American College of Chest Physicians
and Society of Critical Care Medicine Consensus Confer-
ence definitions [17]. Both investigators independently
reviewed the included studies by using a standardized data
collection form. Discrepancies were resolved by discussion.
The Scottish Intercollegiate Guidelines Network checklist
for randomized, controlled trials [18] was used to evaluate
the methodological quality of the identified studies
included in this analysis. A double plus (++) denotes studies
very unlikely to have bias, plus (+) studies where bias is
unlikely, and minus (−) studies with high risk of bias [18].tral Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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Figure 1 Summary of evidence search and selection.
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across studies. Conventional forest plots were prepared
for survival. A statistical difference between groups was
considered to occur if the pooled 95% confidence inter-
val (CI) did not include 1 for the odds ratio (OR). An
OR <1 favored bundled GDT when compared with a
control group. Two-sided P-values were calculated. A
random-effects model was chosen for all analyses. Stat-
istical heterogeneity and inconsistency were assessed by
using the Q and I2 tests, respectively [19,20]. When the
P-value of the Q-test was <0.10, the I2 was >25%, or
both, heterogeneity and inconsistency were considered
significant [19,21].
Randomized controlled trials
The authors of the Surviving Sepsis Campaign recom-
mend the protocolized, quantitative resuscitation of
patients with sepsis-induced tissue hypoperfusion
(defined as hypotension persisting after initial fluid
challenge or blood lactate concentration ≥4 mmol/L)
[1]. They recommend initiating this protocol as soon ashypoperfusion is recognized and it should not be delayed
pending ICU admission. During the first 6 hours of resus-
citation, the recommended resuscitation goals include
all of the following: central venous pressure (CVP) 8 to
12 mmHg; mean arterial pressure ≥65 mmHg; urine
output ≥0.5 ml kg h−1; superior vena cava oxygen satur-
ation (ScvO2) or mixed venous oxygen saturation 70 or
65%, respectively. The primary rationale for this recom-
mendation comes from a randomized, controlled,
single-center study demonstrating that early quantita-
tive resuscitation improved survival for emergency
department patients presenting with septic shock [2].
Resuscitation targeting the physiologic goals noted
above for the initial 6-hour period was associated with
a 15.9% absolute reduction in 28-day mortality (46.5%
versus 30.5%, P = 0.009).
Bundled GDT was also evaluated in a multicenter
trial of 314 patients with severe sepsis in eight Chinese
centers [22]. This trial reported a 17.7% absolute reduction
in 28-day mortality (42.5% versus 24.8%, P = 0.001). A
single-center randomized controlled study from Taiwan in
224 medical ICU patients using the protocol of Rivers and
colleagues [2] also demonstrated a survival advantage with
bundled GDT (hospital mortality, 46.3% versus 28.4%,
P = 0.006) [23]. Most recently, the multicenter ProCESS
trial enrolled 1,341 patients into three treatment groups
(protocol-based GDT, protocol-based standard therapy,
usual care) [24]. No difference in 60-day mortality was
observed between the three groups (protocol-based GDT
versus usual care: 21.0% versus 18.9%, P = 0.830).
These four randomized trials included a total of 2,131
patients; 834 (39.1%) in the bundled GDT arm and 851
(39.9%) in the control arm (446 (20.9%) were in the
protocol-based standard therapy group of the ProCESS
trial). All four studies used the same targeted goals for
fluid administration and for the use of vasopressors.
The reported total IVF administration for shock varied
from 5.0 liters in the control arm of the Taiwanese
study to 3.5 liters in the control arm of the Rivers study
at 6 hours and 2.3 liters at 6 hours in the control arm
of the ProCESS trial (Table 1). Bundled GDT was ap-
plied in the emergency department in two studies
[2,24] and the ICU in two studies [22,23]. Patients who
were treated with bundled GDT did not achieve a sig-
nificant reduction in mortality compared with those in
the control arm (OR 0.609; 95% CI 0.363 to 1.020;
P = 0.059; Figure 2). The trials were inconsistent and
heterogeneous (I2 = 80%, P = 0.002). With removal of the
ProCESS trial, the remaining three trials were without
heterogeneity and were consistent (I2 = 0%, P = 0.915), dem-
onstrating a significant reduction in mortality with GDT
(OR 0.475; 95% CI 0.353 to 0.639; P < 0.001). However,
these three trials combined had fewer patients enrolled
compared to the ProCESS trial.
Table 1 Randomized controlled trials of bundled goal-directed therapy
Study and country Sign score Goal-directed therapy (goals) Time and fluid quantification (L)
Control GDT
Rivers et al. 2001, USA [2] + 500 ml crystalloid bolus every
30 minutes (CVP 8–12 mmHg)
6 h: 3.5 ± 2.4 5.0 ± 3.0
7–72 h: 10.6 ± 6.2 8.6 ± 5.2
Lin et al. 2006, Taiwan [23] + 500 ml crystalloid bolus every
30 minutes (CVP 8–12 mmHg)
Total: 5.0 ± 2.9 5.2 ± 4.0
GDT Collaborative Group of Zhejiang
Province 2010, China [22]
- 500 ml crystalloid bolus every
30 minutes (CVP 8–12 mmHg)
Quantified but not reported
ProCESS 2014, USA [24] ++ 500 ml crystalloid bolus every
30 minutes (CVP 8–12 mmHg)
6 h: 2.3 ± 1.9 2.8 ± 2.0
Double plus signs (++) indicate studies with very unlikely bias, a single plus sign (+) indicates studies with unlikely bias, and a minus sign (−) indicates studies
with high risk of bias. CVP, central venous pressure; GDT, goal-directed therapy.
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Eighteen observational trials of bundled GDT were identi-
fied [25-42] (Table 2). Seven of these trials were assessed
in an earlier analysis demonstrating that a bundled care
protocol for septic shock that included the elements of
GDT was associated with a significant improvement in
hospital survival [15]. Across the 18 studies, the effect of
bundled care on survival was heterogeneous and incon-
sistent (I2 = 32%, P = 0.091; Figure 3). However, when the
study by Ferrer and colleagues [33] was removed, the
remaining 17 studies were without heterogeneity and were
consistent (I2 = 0%, P = 0.796). Overall, there was a statisti-
cally significant increase in the odds of surviving with
bundled care compared with controls when all studies
were examined (OR 0.580; 95% CI 0.501 to 0.672;
P < 0.0001). Statistical significance was maintained when
the Ferrer study was removed from the analysis (OR
0.561; 95% CI 0.499 to 0.631; P < 0.0001).Figure 2 Effect of bundled goal-directed therapy (GDT) on the
odds ratio of survival (95% confidence interval (CI)) for the four
randomized trials analyzed (odds ratio 0.609; 95% CI 0.363 to
1.020; P = 0.059; I2 = 80%, P = 0.002). Rivers et al. 2001 [2]; Lin et al.
2006 [23]; Zhejiang province 2010 [22]; ProCESS 2014 [24].Limitations of the bundled goal-directed
therapy studies
One of the proposed main limitations of the pivotal Rivers
trial is the lack of generalizability of the study. For ex-
ample, Ho and colleagues [43] examined 4,784 emergency
department patients and found only 40 (0.8%) were candi-
dates for bundled GDT. Moreover, these investigators
found patient mortality to be 26.0%, much lower than the
mortality observed in the control arm of the Rivers study,
which was 46.5%, and the control arm mortality in the
other two older randomized trials of bundled GDT
[2,22,23,43]. Variability in mortality was also observed in
the 18 observational studies examined where the mortality
of the control arms ranged from 15.5% to 67.6% [25-42].
Interestingly, the ProCESS trial had one of the lowest ob-
served mortality rates in their control arm at 18.9%. Other
limitations of these trials include resuscitation protocol
complexity, potential risks associated with elements of the
protocol (especially the use of dobutamine and red blood
cell transfusions), and financial and infrastructure implica-
tions necessary to carry out these protocols. For example,
in the Rivers trial the bundled GDT patients had a dedi-
cated investigator to ensure compliance with the study
protocol and had central venous catheters placed to con-
tinuously assess ScvO2.
The observational studies of bundled GDT have a num-
ber of other important limitations, foremost being their
lack of scientific rigor (Table 2). It is also important to
note that the earlier meta-analysis of seven of these trials
found that only time to antibiotic administration (in
hours) between bundle and control patients was consist-
ent between studies, whereas crystalloids, vasopressors,
inotropes, packed red blood cell transfusion, corticoste-
roids, and drotrecogin alfa (activated) exhibited signifi-
cant heterogeneity between the studies [15]. The overall
importance of timely antibiotic therapy was further
supported by the analysis of the Spanish study that
examined 2,319 patients showing a reduction in mortal-
ity with bundled GDT [33]. In a subsequent analysis of
Table 2 Observational controlled trials of bundled goal-directed therapy
Study and country Sign score Goal-directed therapy (goals) Time and fluid quantification (L)a
Control Bundled GDT
Cardoso et al. 2010, Portugal [42] (−) 500 ml to 1000 ml crystalloid bolus, or 300 ml
to 500 ml colloid bolus to achieve CVP ≥12 mmHg
Quantified but not reported.
Castellanos-Ortega et al. 2010, Spain [35] (−) 500-1000 ml crystalloid bolus, additional fluid
to achieve CVP ≥8 mmHg
Quantified but not reported.
El Solh et al. 2008, USA [31] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg 6 h: 2.5 ± 1.0 3.9 ± 2.0
24 h: 3.2 ± 1.3 4.9 ± 2.5
Ferrer et al. 2008, Spain [33] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg Quantified but not reported
Gao et al. 2005, UK [36] (−) Immediate fluid bolus of 0.5 L Quantified but not reported
Girardis et al. 2009, Italy [34] (−) Fluids targeting CVP >6 mmHg or a global end-diastolic
volume by trans-pulmonary thermodilution >700 ml/m2
Quantified but not reported
Heppner et al. 2012, Germany [39] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg Quantified but not reported.
Jones et al. 2007, USA [30] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg 6 h: 2.5 ± 2.4 4.7 ± 1.8
Kortgen et al. 2006, Germany [27] (−) CVP 8–12 mmHg or intrathoracic blood volume
index 850–1000 ml/m2
6 h: 2.8 [1.8,3.8] 2.5 [1.6,3.9]
Lefrant et al. 2010, France [41] (−) ≥20 ml/kg crystalloids or colloids within 6 hours 6 h crystalloid: 1.0 [0.5,2.0] 1.5 [0.5,2.0]
6 h colloid: 0.5 [0.5,1.0] 1.0 [0.5,1.1]
Micek et al. 2006, USA [25] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg In ED: 2.8 ± 1.6 3.8 ± 1.7
Miller et al. 2013, USA [38] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg Quantified but not reported.
Na et al. 2012, Asia [40]b (−) Fluid bolus to achieve CVP >8 mmHg by 6 hours In ED: 1.5 [1.0,2.5] 1.5 [0.9,2.7]
In ICU: 7.8 [5.2,11.6] 5.6 [3.3,9.2]
Nguyen et al. 2007, USA [29] (−) CVP ≥8 mmHg In ED: 2.8 ± 1.5 2.8 ± 2.1
72 h: 7.8 ± 5.2 7.9 ± 6.1
Pestaña et al. 2010, Spain [37] (−) Crystalloid within 6 hours to achieve CVP ≥8 mmHg
or global end-diastolic volume index ≥680 ml/m2
Quantified but not reported.
Sebat et al. 2005, USA [32] (−) 1000 ml crystalloid in ED, 600 ml increments per
MAP & UO protocol
Quantified but not reported.
Shapiro et al. 2006, USA [28] (−) 500 ml crystalloid bolus, repeat until CVP 8–12 mmHg 6 h: 2.9 ± 1.8 4.1 ± 2.6
24 h: 6.5 ± 4.5 7.6 ± 3.9
Trzeciak et al. 2006, USA [26] (−) 250-1000 ml crystalloid bolus until CVP ≥8 mmHg ED: 3.5 ± 2.3 5.7 ± 3.0
ICU 24 h: 5.5 ± 4.9 2.8 ± 1.7
ED and ICU 24 h: 9.1 ± 5.1 7.9 ± 3.4
Double plus signs (++) indicate studies with very unlikely bias, a plus sign (+) indicates studies with unlikely bias, and a minus sign (−) indicates studies with high risk of bias. aValues expressed as mean ± standard














Figure 3 Effect of bundled goal-directed therapy (GDT) on the
odds ratio of survival (95% confidence interval (CI)) for the 18
observational trials analyzed. All 18 studies: odds ratio, 0.580; 95%
CI 0.501 to 0.672; P < 0.0001 (I2 = 32%, P = 0.091). With the Ferrer study
[33] removed: odds ratio 0.561; 95% CI 0.499 to 0.631; P < 0.0001
(I2 = 0%, P = 0.796).
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pliance with four therapeutic goals and four treatments
employed in their bundle [44]. Only timely administra-
tion of antibiotics and drotrecogin alfa (activated) for
multiorgan failure were associated with significantly
lower mortality [44].
Another important limitation of both the randomized
trials and the observational studies examining bundled
GDT is that multiple interventions occurred that could
potentially influence patient outcome. This is supported
by the observation that statistical differences in the use of
vasopressors, red blood cell transfusions, corticosteroids,
and timely administration of antibiotics existed between
study arms when the trials reporting specific interventions
were combined for analysis (Table 3). Moreover, across
the 12 studies reporting on IVF administration, most
showed greater fluids administered to patients receiving
bundled GDT (median (interquartile range): 3,875 ml
(2,638 ml, 4,901 ml) versus 2,779 ml (2,332 ml, 3,342 ml);
P = 0.143) (Tables 1 and 2). However, the studies were in-
consistent and significant heterogeneity existed between
studies for the difference in IVFs administered bytreatment group (I2 = 90%, P < 0.001) (Figure 4). Removal
of any one study failed to significantly reduce heterogeneity
(I2 remained 87% to 91%, with P < 0.001).
For completeness, one additional observational study
was identified but not included in our analysis due to its
makeup. This was a multicenter quality improvement
study conducted in the United States, Europe, and South
America utilizing a multifaceted intervention to facilitate
compliance with selected guideline recommendations for
the management of severe sepsis [45]. This intervention
included the use of a CVP greater than 8 mmHg to target
fluid administration. Data on 15,022 patients at 165 hospi-
tals were included in the analysis. Compliance with the
initial 6-hour bundle targets increased linearly from 10.9%
of subjects in the first quarter to 31.3% by the end of
2 years of the quality improvement campaign. This was
associated with a significant reduction in mortality over
the same time period (37.0% in the first quarter in
the campaign to 30.8% by 2 years, P = 0.001). After
adjustment for baseline characteristics, administration of
broad-spectrum antibiotics, obtaining blood cultures before
antibiotic initiation, administration of drotrecogin alfa
(activated) in the first 24 hours, achieving plateau pressure
control, and maintaining blood glucose control were all as-
sociated with lower hospital mortality. In those with septic
shock, there was no association between mortality and the
ability to achieve a CVP ≥8 mmHg or demonstration of
ScvO2 ≥ 70% [45].
The limitations of the available clinical studies of bun-
dled GDT, to include the inconsistent results regarding
IVF administration, have served as the major impetus
for the conduct of three multicenter trials examining the
elements of GDT (ARISE in Australasia, ProMISe in the
United Kingdom, and ProCESS in the United States)
[24,43,46]. These trials have similar structures, interven-
tions, and patient entry criteria that will allow the trial
investigators to collaboratively conduct a prospective
individual patient data meta-analysis, using the raw data
from each trial [46]. With over 4,000 subjects combined,
these trials are powered to find smaller effects on
outcome and to better explore subgroups. The ProCESS
trial has already been published and showed that proto-
colized GDT did not reduce mortality compared with
usual care [24]. However, patients in the usual care arm
received significantly less IVF at 6 hours and had a nu-
merically lower mortality compared to the protocolized
GDT arm.
Conclusion
Clinicians caring for critically ill patients must always
weigh the benefits and risks of administered therapies to
include the use of IVFs. Our meta-analysis supports the
findings of an earlier analysis [15] demonstrating that
IVF volume was not consistently altered by the use of
Table 3 Comparison of specific interventions employed in trials of bundled goal-directed therapy













ProCESS [24] 201/456 241/439 4/456 35/439 34/456 63/439 37/456 54/439 0/456 1/439 442/456 428/439 NA NA
Rivers et al. [2] 40/133 36/130 1/133 18/130 25/133 83/130 NA NA NA NA 125/133 126/130 123/133 112/130
Lin et al. [23] 81/116 80/108 16/116 13/108 43/116 39/108 25/116 32/108 NA NA 107/116 102/108 NA NA
El Solh et al. [31] NA NA NA NA 11/87 12/87 14/87 83/87 2/87 11/87 73/87 84/87 79/87 83/87
Ferrer et al. [33] 329/854 630/1,465 NA NA NA NA 311/854 611/1,465 51/854 74/1,465 568/854 1,009/1,465 NA NA
Jones et al. [30] 27/79 53/77 1/79 2/77 1/79 4/77 5/79 31/77 3/79 3/77 NA NA NA NA
Kortgen et al. [27] NA NA 0/30 6/30 5/30 5/30 13/30 30/30 0/30 7/30 28/30 28/30 30/30 30/30
Lefrant et al. [41] NA NA 40/230 20/215 24/230 34/215 91/230 122/215 0/230 4/215 NA NA 141/230 145/215
Micek et al. [25] 60/60 43/60 NA NA 4/60 12/60 30/60 13/60 7/60 2/60 43/60 52/60 36/60 52/60
Na et al. [40] 171/364 135/192 144/364 78/192 17/364 4/192 NA NA NA NA NA NA NA NA
Nguyen et al. [29] 39/77 111/253 18/77 67/253 11/77 32/253 23/77 41/253 6/77 4/253 NA NA 77/77 227/253
Shapiro et al. [28] 23/51 63/79 1/51 6/79 3/51 8/79 12/51 23/79 0/51 3/79 45/51 77/79 48/51 78/79





























P-valuesa <0.001 0.249 <0.001 <0.001 0.308 0.636 0.008














Figure 4 Effect of bundled goal-directed therapy (GDT) on the
standardized paired difference (Std diff) of the means for
intravenous fluid use based on study defined resuscitation
goals (I2 = 90%, P < 0.001). CI, confidence interval.
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ing their quantitative use cannot be made. Clinicians
should at least be aware of the potential for harm due to
the excessive administration of IVFs to patients with
septic shock.
Abbreviations
CI: Confidence interval; CVP: Central venous pressure; GDT: Goal-directed
therapy; IVF: Intravenous fluid; OR: Odds ratio; ScvO2: Superior vena cava
oxygen saturation.
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